Compare Enact Holdings Inc (ACT) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs GSK plc — how do they compare? Enact Holdings Inc trades at $45.26 (market cap $6.35B), while GSK plc trades at $52.83 (market cap $105.91B). The key difference: GSK plc is far larger — about 16.7× Enact Holdings Inc's market cap, and GSK plc pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| ACT | GSK | |
|---|---|---|
Market Cap | $6.35B | $105.91B |
Sector | Technology | Health |
52-Week High | $45.71 | $61.18 |
52-Week Low | $34.39 | $36.20 |
Enterprise Value | $6.55B | $126.53B |
Dividend Yield | 1.91% | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
GSK trades at $53.32, down 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $1.24 EPS, and maintains robust profitability with a 17.78% net income margin. Recent FDA approval for Utebzi and the $10.6 billion acquisition of Nuvalent highlight strategic expansion in oncology and anti-infectives.
Outlook remains positive with 7-9% EPS growth guidance for 2026, though risks include integration of large acquisitions and patent cliffs. Analyst consensus is mixed with 31% buy ratings, but solid fundamentals and recent approvals support a constructive view for long-term investors amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
